Hepatitis B Virus Vaccine – Epidemiology – Mature Markets
DRG Epidemiology's coverage of the Hepatitis B vaccine comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report the prevalence of the Hepatitis B vaccine for each country, as well as annualized case counts projected to the national population.
DRG Epidemiology's Hepatitis B vaccine forecast will answer the following questions:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of the Hepatitis B vaccine over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
DRG Epidemiology provides at least ten years of forecast data for the following Hepatitis B vaccine patient populations:
Vaccine eligible population Newly eligible for vaccine population Note: coverage may vary by country and region.
Table of contents
- Hepatitis B Virus Vaccine - Epidemiology - Mature Markets
- Introduction
- Key Findings
- Overview
- HBV Vaccine-Eligible Population per 1,000 children in 2021 and 2041
- HBV Vaccine-Eligible Population per 1,000 Adolescents in 2021 and 2041
- HBV Vaccine-Eligible Population per 1,000 Adults in 2021 and 2041
- Relative Sizes of the Contributing Factors to the Trend in Total Eligible Pediatric Population for the HBV Vaccine Over the Next 20 Years.
- Relative Sizes of the Contributing Factors to the Trend in Total Eligible Adolescents Population for the HBV Vaccine Over the Next 20 Years.
- Relative Sizes of the Contributing Factors to the Trend in Total Eligible Adults Population for the HBV Vaccine Over the Next 20 Years.
- Key Findings
- Epidemiology Data
- Methods
- HBV Vaccine Eligible Population
- Reference Materials
- Literature Review
- Studies Included in the Analysis of the HBV Vaccine Eligible Population
- Studies Excluded from the Analysis of the HBV Vaccine Eligible Population
- Risk/Protective Factors
- Risk/Protective Factors for the HBV Vaccine Eligible Population
- Bibliography
- Abbreviations table
- Glossary
- Literature Review
- Introduction
Jagriti Prasad, M.P.H., is an associate epidemiologist at Clarivate. Previously, she worked on a research project exploring trends in a rare cancer and its subtype using data spanning 44 years in the largest cancer registry of northern England (NRYPMDR). She obtained her M.P.H. from Newcastle University (U.K.) and her B.D.S. from Manipal University (India).
Mudasir Khan, M.P.H., is a senior epidemiologist at Clarivate. His areas of expertise are oncology and psychiatry diseases. He holds a master’s degree in public health from the Tata Institute of Social Sciences in Mumbai.